Catalogue for Pharmacist

Diabetes Patient Information

This page is intended for healthcare professionals.

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: diabetes, haemophilia, growth disorders and obesity. This page provides access to a range of support materials that you can utilise to support your patients living with diabetes.

Diabetes Patient Educational Information

A home monitoring diary and range of patient educational information in printed and electronic format are available to support your patients when managing their diabetes care and are intended to provide educational support and supplement your advice.

Patients Getting Started Leaflets

If you have made a decision to start a patient on a Novo Nordisk diabetes medicine, there are insulin safety cards and ‘Guidance for patients leaflets’ for each medicine which are intended to support patients getting started on their treatment and to supplement your advice. They are not intended to affect your prescribing decisions.

Links to Prescribing Information for each medicine are available below for reference.

Actrapid® (Insulin human, rDNA)

For Prescribing Information please click here

Fiasp® (Fast-acting insulin aspart)

For Prescribing Information please click here

Glucagen® (Glucagon)

For Prescribing Information please click here

Insulatard® (Insulin human, rDNA)

For Prescribing Information please click here

Levemir® (Insulin detemir)

For Prescribing Information please click here

NovoMix® 30 (Biphasic insulin aspart)

For Prescribing Information please click here

NovoRapid® (Insulin aspart)

For Prescribing Information please click here

Ozempic® (Semaglutide)

For Prescribing Information please click here

Tresiba® (Insulin degludec)

For Prescribing Information please click here

Victoza® (Liraglutide)

For Prescribing Information please click here

Xultophy® (Insulin degludec/liraglutide)

For Prescribing Information please click here

(Please note: the links will open the page in a new browser window).

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.

Information and resources listed on this page are provided by Novo Nordisk Limited.

UK20DI00122 Date of preparation: May 2020

 

We do not currently have any materials for this product group.